OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

Company Number 06884476

YORK AGAINST CANCER

A company limited by guarantee and A registered charity number 1130835

REPORT AND ACCOUNTS

For the year ended 31 December 2024

HPH Chartered Accountants 54 Bootham York YO30 7XZ

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

CONTENTS

Page
Chairman’s Report 1
Trustees’ Report 2 - 22
Auditor’s Report 23 – 26
Statement of Financial Activities 27
Balance Sheet 28
Cash Flow Statement 29
Notes to the Financial Statements 30 - 40

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

CHAIRMAN’S REPORT 2024

2024 was again a busy year for the Charity and the success of the Leveson Centre has certainly given York Against Cancer a further boost in visibility, meaning more people are now aware of what we do and can take advantage of the many services on offer. The feedback from users is extremely positive, and we thank the staff and volunteers who deliver this service in such a professional manner. Our local MPs helped to celebrate our opening and first year anniversary, and this was followed by an unexpected, but welcome, visit from the Prime Minister [Rishi Sunak] who took time out to speak to everyone and send his best wishes.

As the Charity has continued to grow, it is important that our processes can keep pace, so we are able to continue to do the things that make the Charity unique. Strategically we have acknowledged the need for more focus in certain areas with the appointment of an External Relations Manager and Community Fundraiser. Their role is to ensure we can harness the undoubted goodwill of the people and businesses of York and North Yorkshire to keep awareness in the forefront at a time of significant challenge for charities. We are fortunate that the work we do, alongside our solid reputation, means we maintain a high level of support from users and others, with legacies continuing to provide a vitally important income to support the many services that are offered.

The Charity has, for many years, supported research at York University for the Jack Birch Unit, a world-renowned centre investigating bladder cancer. The Unit has been led since 1999 by Professor Jenny Southgate, who will be retiring in 2025. We are pleased to announce that Will Brackenbury will be Jenny’s successor, and we wish Jenny a long and happy retirement.

After many years as a Trustee, Mike Stower has stepped down from the Board of Trustees, although he continues to volunteer at events and in the Leveson Centre. We are all grateful for his past and continuation contribution to the work of the Charity.

Many of our volunteers work within the retail arm of the Charity, manning the shops at both the Community Stadium and the Hospital. Sales have continued to grow at both locations, due in no small part to their efforts and the excellent range of goods made available by the astute buying of our retail management team.

Our small office team are usually the first point of contact for the Charity, and along with our minibus drivers continue to work hard throughout the year. To them, our volunteers, and Board colleagues I would, once again, like to pass on my grateful thanks for your continuing support and promotion of the Charity.

Once again, we sadly lost a number of our volunteers and supporters throughout the year, and our thoughts go out to their families and friends. Each one of them supported the work of the Charity, and helped it continue to provide the important services and funding for research that we are recognised for.

Ian Yeowart

Chair York Against Cancer

www.yorkagainstcancerorg.uk 1

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Directors (who are also the Trustees of the Charity and are listed below) are pleased to present their report of the Charitable Company for the year ended 31 December 2024.

Objectives and activities

The objects of the Charity are to raise funds to:

  1. Foster and promote joint research between clinicians and research scientists in York and wider area and, by encouraging a more effective exchange of ideas and information, to advance the alleviation and cure of cancer.

  2. Support treatment of cancer patients at York Hospital and the local area.

  3. Fund education and information about cancer for patients and their families and the wider public.

The Trustees believe they have complied with the duty in section 4 of the 2006 Charities Act to have due regard to guidance published by the Charity Commission in respect of public benefit.

Aims and strategies

The Charity aims to provide support to cancer patients and the community through the: -

The Team

The team is made up of a small group of dedicated people who, together, cover the main office, retail, the Leveson Centre and the minibus service. Each member of the team has their own responsibilities but the flexibility and ability to cover each other’s roles should not be underestimated.

The team has annual appraisals where individuals are given the opportunity to discuss the previous year’s targets, to celebrate achievements and discuss any concerns. The team are encouraged to discuss any training requirements they consider relevant to their role, which may be useful for their personal development.

The team are required to undertake training to enable them to do their roles safely and to meet minimum criteria ensuring general compliance. This includes health & safety, manual handling, safeguarding (relevant staff only) and G.D.P.R.

www.yorkagainstcancerorg.uk 2

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

CARE GROUP – SERVICES AND SUPPORT 2024

During 2024 Mike Stower, stood down from his role as Care Group Chairman after 5 years in the role, and as a Board member. He, however, remains heavily involved with the Charity as a volunteer at The Leveson Centre. The Care Group and the Board of Trustees wish to thank Mike for his hard work and leadership throughout his tenure.

With this change we have taken the opportunity to update the Group’s Terms of Reference and the process for applying for, and subsequent assessment of, the funding for new projects. We have also undertaken a skills audit of the Group’s membership to identify skills gaps and invited clinical experts to join the Group.

New applications / requests for project funding are always welcome and will be progressed if they pass the Group’s agreed assessment process. To be successful a project must show clear evidence that it represents value for patients, has longevity and fulfils the over-arching aims of the charity in providing benefits to those affected by cancer be they patients, family members or carers.

During 2024 York Against Cancer funded many services and projects including:

And also:

Most of these projects are for a fixed term contract, (usually 2 or 3 years), and are reassessed before being renewed or otherwise. With all care project funding real-time and ongoing assessments are essential to ensure that the charity is getting value. Recommendations can be made to the Board part-way through a fixed contract for either an increased budget or time extension if the Group considers this to be appropriate. However, such adjustments are only proposed if there is good evidence that the service is proving to be popular (as measured by uptake) and is considered to be effective.

As a charity we continue to support the running costs of the Mobile Chemotherapy Unit (MCU) that provides “local” chemotherapy services away from York Hospital. Initially, in 2017, YAC funded the construction and project management of the MCU before handing its management to York Hospital. However, we remain committed to the maintenance and operation of the unit. In 2024 the MCU provided Chemotherapy treatments ‘closer to home’ for cancer patients in Selby, Malton and Bridlington.

www.yorkagainstcancerorg.uk 3

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Our working relationship with the York & Scarborough Hospital trust and the local health community remains very strong. This is made possible by having clinicians - consultants, nurses - and administrators from the hospital together with representatives from the local health community as members of the Care Group. This is supplemented by YAC attending meetings of the hospital Cancer Board where issues and concerns can be approached collaboratively.

Below is a selection of information on some of the services we provide:

Minibus

Our minibus service which provides free transport for patients attending St James Hospital in Leeds for radiotherapy treatments continues to be popular and much appreciated. During 2024 we provided 86 individual patients with transport to Leeds – radiotherapy is given daily (MonFri) and length of treatments can range from 3 to 7 weeks. If the demand is high, we use the minibus and our volunteer drivers, but if demand is low, we use the YAC car, thereby making the service more efficient.

Minibus passengers per month

----- Start of picture text -----
20
15
10
5
0
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
2022 2023 2024
----- End of picture text -----

Feedback from minibus service users.

----- Start of picture text -----
To put this service on every day for
‘I have been so grateful for the people like myself who would
service I have received.’ normally struggle to get to Leeds
is brilliant.’
----- End of picture text -----

www.yorkagainstcancerorg.uk 4

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Transport to Rapid Diagnostic appointments.

We have supported patients under the care of the Rapid Diagnostic Centre at York & Scarborough Hospitals helping to provide transport for those who need to attend a diagnostic appointment, most commonly not at their local hospital (for example transport to Castle Hill Hospital, Hull) and at short notice, when other transport options are not available.

We have provided transport to these types of appointments since 2021 and during 2024 we have helped 43 patients from York, Malton and Scarborough at a cost of £4054 p.a.

Respite break figures – quarter 4 - 2024

----- Start of picture text -----
FILEY YAPHAM
10 10
8 8
6 6
4 4
2 2
0 0
Oct Nov Dec Oct Nov Dec
Breaks available breaks taken Breaks available breaks taken
----- End of picture text -----

We are currently able to offer free self-catering respite breaks in Filey and Yapham

Number of guests per stay

Guest numbers 1 to 2 3 to 4 5 to 6 7 to 8
Sept 1 3 2 3
Oct 0 2 3 1
Nov 1 2 3 1

Filey is very popular because it is by the sea and has more space (4 double bedrooms) and is therefore suitable for families / groups of friends. Yapham, on the other hand, having only 1 bedroom, is ideal for couples looking the peace and quiet of a few days in the country.

Feedback from guests at Filey

‘The Bay respite house was truly a lovely break for our young family. A beautiful space to relax & spend quality time together.’

‘A fabulous, cosy place which we absolutely loved – thank you so much!’

www.yorkagainstcancerorg.uk 5

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Feedback from guests at Yapham

‘The cottage was so relaxing & it was great to spend time away from all the medical appointments & treatments & to be able to fully unwind.’

‘Such a beautiful & comfortable holiday house, we sat outside & ate our breakfast watching the Alpacas and sheep …. So relaxing.’

We encourage feedback from service users to ensure we get to know of any issues and to maintain high standards. If any improvements need addressing, we act on these quickly. Above is some of the feedback we have received .

Cancer Benefits Advice Service – Scarborough – in collaboration with Citizens Advice North Yorkshire

The charity continues to fund a cancer benefits advice service providing holistic financial advice for cancer patients in the Scarborough area, ensuring they receive the financial help to which they are entitled.

The main issues faced by clients by proportion are shown as follows:

ISSUE– Patients Concerns 2023-24 2022-23
∙Benefits 78% 97%
∙Charitable applications 12% 28.5%
∙Health & Community Care 4% 5%
∙Debt 1% 2%
∙Financialservices 3.5% 3.5%
∙Employment 1.2% 1.5%
∙Housing 1% 2%
∙Travel&Transport 5.6% 5%

As demonstrated by these figures, the issue of Benefits remains highest. However, the increased complexity of clients’ situations has resulted in addressing a broader range of issues including referrals to food banks, to the Household Support Fund for fuel vouchers and to local charitable support for essential household items.

We obtained a total of £542,926, of confirmed monetary benefit for clients in the last 12 months, with the expected outcomes to reach even greater sums. 320 clients were supported with new awards or increases in existing benefits, reaching income gains of £527,320. Clients and their families have acknowledged they would have struggled to achieve any of this without our help.

www.yorkagainstcancerorg.uk 6

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Cancer Benefits Advice Service - York

We have had a strong year of collaboration to help people affected by cancer in York.

This financial year we have seen 276 clients and helped them with 1,029 issues.

Most of these issues we helped with were working out benefits entitlements and helping people to claim the benefits which were due to them. We helped people to claim £928,919 of benefits. Most of these benefits were in the form of Personal Independence Payments and Attendance Allowance.

However, we provide fully holistic advice, and we also advise on charitable support, hate crime, housing, relationships and family, travel and transport and utilities.

We helped people aged between 30 and 94 and this was evenly split between women and men. We have noticed a trend of younger people using the service year on year. 87% of people using this service said that it improved their mental health and 89% of people would recommend the service to others.

Citizens Advice York are pleased to be working with York Against Cancer to provide a valuable service to people when they most need it.

Adult Psychology

The Clinical Psychology service for adults is offered from the Leveson Centre by Dr Joanne McVey (Jo). This service commenced in 2023 and during 2024 we have seen consolidation of the service, we are now seeing its real value for patients and their families.

During 2024, Jo saw 17 individual referrals for a total of 64 sessions, at a cost of £8,782. These are on Tuesday afternoons, mainly face to face. This input has been much appreciated by people living with cancer who were able to access psychological input quickly and easily in a venue that was familiar to them.

Jo has also trained to become a HOPE (Help Overcoming Problems Effectively) facilitator and has co-facilitated a HOPE course during November/ December with Debbie Smith the Leveson Centre Manager, there are more planned for 2025. Between 4 and 6 participants attended the course and results were very positive, with group attendees remaining in touch with each other for peer support. Subsequent courses are already being signed up for and both Jo and Debbie are working closely with York Hospital to spread the word and promote the courses.

www.yorkagainstcancerorg.uk 7

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Young People’s Psychology service

The York against Cancer Teenage and Young Adult Psychology Service continues to offer Clinical Psychology support to young people aged 12 to 25 coping with cancer in their family alongside all the usual demands of adolescents into adulthood. The service continues to grow and evolve, with demand in 2024 being the highest since the service began in 2018. The service is entirely provided by Dr Becky Donaldson, Child/ Adolescent Clinical Psychologist, at present. Becky’s therapy dog, Luna (fully registered with Pets as Therapy charity) is an almost constant fixture in her therapeutic work and the young people love her being part of the sessions at the Leveson Centre.

Families can bring their teenage/ young adult family members for appointments at the Leveson Centre, with a small minority choosing Becky’s Selby clinic which may be a more convenient location or because a different day/ time is preferred. The service also offers online appointments, which are popular with young adults juggling cancer in their family with being away at university, or students fitting the support around their GCSE or higher education revision and exams.

In 2024, the service completed 207 teen/ young adult sessions. It also provided psychological consultation/ advice/ recommendations to school and parents in support of young people on occasions. Where safeguarding concerns are identified, these are also key points of essential liaison and contribution. In addition, the Leveson Centre has also accessed Becky’s clinical child psychology advice when needed, such as for signposting to support for Under 12s (which is largely web-based resources due to severe lack of provision for this cohort). The service has also provided the Leveson Centre with written resources / signposting for issues that may arise in general conversation with visitors to the centre (e.g. how to talk to a child about cancer/ illness/ end of life; resources for young people who are self-harming).

In December 2024, Dr Simon Baker, York University invited Becky to contribute to a school’s project he is running to develop materials to support Science teachers as they teach cancer/ illness themes at Key stage 3&4. This project will evolve in 2025. The Teen service can also contribute to any child/adolescent projects provided by York against Cancer, such as the Primary school book bag project, designing an emotionally supportive fact sheet for parents/carers on ways to talk to their child about cancer – a common worry for families navigating cancer diagnosis and beyond.

Dr Becky Donaldson, Chartered Clinical Psychologist

Becky’s therapy dog, Luna

www.yorkagainstcancerorg.uk 8

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Leveson Centre: Providing Cancer Support Services

As we reflect on 2024, The Leveson Centre has continued to grow as a vital support hub for individuals affected by cancer. Between January to December 2024, the centre recorded 9,896 points of contact — including visits, phone calls, and emails.

In early January 2024, Debbie (Centre Manager) and Victoria (Assistant Manager) took time to reflect on the successes of 2023 and plan for the year ahead. Looking back, 2024 has seen significant growth in our services, thanks to valuable feedback from those who use the centre.

Our Core Services

The Leveson Centre offers comprehensive support to both patients and their families throughout diagnosis, treatment, and beyond. Through peer support and one-on-one services, we provide a range of well-being focused activities, including:

New Services Introduced in 2024

To meet growing demand and offer continuing support, we have expanded our services to include:

www.yorkagainstcancerorg.uk 9

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Driving Growth and Building Connections

This expansion has been driven by positive feedback and word-of-mouth recommendations from service users, which has made Health Care providers more confident to recommend our services to patients. Also, as a result of this we are seeing a considerable uplift in the numbers of people who just drop in for a chat and a drink.

The Leveson Centre remains committed to providing a welcoming and supportive environment for everyone navigating their cancer diagnosis.

Paul "The Leveson Centre has been a god send. It’s like family and its helping with my treatment, but it’s not a hospital. When you’re in a hospital, immediately it’s clinical; it’s sterile. Here, it’s just so relaxing and there’s so much on offer.”

John "To anyone thinking of coming to The Leveson Centre, I would encourage them to come. It’s not clinical, but it can help regardless of whatever type of cancer you’ve got. There’s all sorts of exercise classes, therapies and everything that can help, and the staff are really friendly."

Pauline Family member “ (the Leveson Centre) has lifted us. We have dark days but we know the Leveson centre’s here”

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit (MCU) takes chemotherapy services to the wider areas of the York & Scarborough Hospital Trust, in Malton, Selby, Scarborough and Bridlington, this has enabled the charity to widen its reach. The MCU has helped thousands of patients avoid the timeconsuming and tiring journeys to the hospital in York. During 2024 we continued to fund the cost of servicing and repairs to keep the MCU on the road.

www.yorkagainstcancerorg.uk 10

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

RESEARCH ACTIVITIES

Jack Birch Unit (University of York) – Molecular Carcinogenesis

The Jack Birch Unit has continued to expand with recruitment of Dr Vicki Jennings in December 2024 to a five-year research fellowship supported by York Against Cancer. Vicki is a cancer immunologist by training and will be studying the development and use of immunotherapies for epithelial cancers, including bladder cancer. Vicki joins Dr Simon Baker and Dr Andrew Mason as the third independent group leader working in the Jack Birch Unit. This is likely to be one of the last major changes to the JBU instigated under the current directorship of Professor Jenny Southgate, who is planning retirement in summer 2025 after 25 years at the helm! In preparation of this, a scientific review of the last five-year programme was submitted for external scientific review, securing the way for future funding of the JBU under a new Director.

Dr Vicki Jennings at her desk in the JBU

Simon has made progress studying how a common virus, (“BK virus”), may cause bladder cancer. This work has been gaining recognition, with Simon invited to give talks around the UK and internationally, in Germany, Italy and Switzerland. Simon was awarded funding from The Urology Foundation for a study using samples from the “Malmö Diet and Cancer Study” biobank in Sweden to study whether BK virus infections relate to future development of bladder cancer. Diane Lee entered Simon’s group as a PhD student funded by Kidney Research UK, joining York Against Cancer’s PhD student George Hatton, now in his 2[nd] year.

Andrew’s cancer informatics group has expanded, with several postgraduate students joining to study different aspects of cancer informatics. Richard Gawne left to take up a place on the NHS bioinformatics training programme and was replaced, in September, by Marcello Beltrami. Andrew has also been busy delivering talks, including bladder cancer results from analysis of Genomics England’s 100,000 genomes project, where Andrew has a leading role.

Debora Morgante, Vlad Ungureneau and Ryan Ellison all submitted their PhD theses and passed their viva examinations subject to minor corrections. Debora has returned to her job as a Consultant Paediatric surgeon, Ryan has taken up a job in medical writing and Vlad has returned to Romania where he is applying for postdoctoral positions.

Internationally, the JBU received major recognition at the International Bladder Cancer Network meeting in Bern Switzerland. Jenny was invited to deliver The 2024 IBCN lecture and during the conference was awarded Honorary Membership as a lifetime achievement award for her contribution to bladder cancer research. At the same meeting, Andrew and Simon both gave research talks – with Simon's selected as the best research talk.

Andrew, Jenny & Simon taking in the scenery at the IBCN conference in Bern

www.yorkagainstcancerorg.uk 11

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

In my final report as JBU Director, I would like to give a very personal thank you to everyone at York Against Cancer for the fantastic support given to the JBU over the years. I further thank my colleagues and our scientific and clinical collaborators for their major contribution to the quality and output of our research.

Professor Jenny Southgate, Director, Jack Birch Unit of Molecular Carcinogenesis, University of York

https://www.york.ac.uk/biology/jack-birch-unit/

Clinical Trials Research Nurse and Assistant posts at York Hospital

As of July 2024, York & Scarborough Teaching Hospital NHS Foundation Trust had over 30 Cancer Research studies:

These include.

----- Start of picture text -----
Active Studies by Cancer Site
2
Breast
4 9
1 Colorectal/GI
1
Haematology
Head & Neck
Skin
10 7
Urology
Multi-site
----- End of picture text -----

www.yorkagainstcancerorg.uk 12

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

----- Start of picture text -----
Active Cancer Studies by Research Focus(s)
1 4 Detection & Survellance
13
Chemotherapy
6
Radiotherapy
Support & Rehabilitation
14
Surgery
----- End of picture text -----

----- Start of picture text -----
Enrolled Cancer Patients by Reporting Year
800
691
700
600 514
500 404
400
288
300
192
200
100
0
19/20 20/21 21/22 22/23 23/24
Reporting Year
Cancer Patients recruited
----- End of picture text -----

As you can see from this snapshot, the Cancer Research portfolio is active and thriving, a testament to the support and funding received from York Against Cancer.

www.yorkagainstcancerorg.uk 13

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

EDUCATION ACTIVITIES

The Cancer Awareness and Prevention group continues to work to spread information about cancer across as wide a range of the public as possible with an emphasis on young people.

York Against Cancer Awareness and Education Committee Report 2024

The Communications & Awareness Working Group was created as a sub-committee of The Board of Directors of York Against Cancer in 2024. As Communications & Awareness will be a strategic pillar in the new strategy, to be launched in 2025, it was agreed that the Education & Awareness Working Group and the Communications Working Group should combine to form the Communications & Awareness Working Group, to best support the strategic goals of the Charity. The Terms of Reference of the Group were updated and agreed by the committee in September 2024. The purpose of the group will now be to:

The Enthuse Partnership, which was delivered primarily as teacher training/professional development to train teachers to be more confident in teaching cancer related topics and included events for schools and students to teach young people about cancer research, came to end in the Spring Term of 2024. The next phase for the Enthuse Partnership was approved by the Board of Trustees in October 2024. Building on the success of Phase 1, Phase 2 will be led by Huntington Research School and will focus on PHSE, the curriculum for which changed for 24/25 to include more need for discussion on cancer related topics. In Phase 2, a series of interactive teaching resources for PHSE around cancer will be piloted by Huntington Research School and then delivered regionally by the NSLC.

www.yorkagainstcancerorg.uk 14

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

This will include topics such as:

In Spring 2021, York Against Cancer offered a range of free books to schools in the local area, helping teachers and families to have open conversations about cancer with young people and enabling them to better understand what cancer is, what treatment might involve, and the feelings they may experience around it. These books have been invaluable in supporting teachers and families to have conversations about cancer. It was agreed that this project should be repeated and expanded upon in 2025, with packs of books delivered to 188 primary schools in the region.

York Against Cancer’s annual Awareness Day was held in October in the centre of York. This provided a valuable opportunity to engage with the public about the work of the charity, the research being conducted by the Jack Birch Unit, and raise funds.

A new Social Media Strategy was created to grow our supporter base to raise awareness of the charity and its services and increase opportunities for income generation. It was agreed that the charity would cease posting on the platform X, as its values do not align with York Against Cancer. Accounts were created on Bluesky and Threads and will continue to be monitored to see if our audience engage with these platforms. To support the development of our social media channels, videos and photos will be commissioned in 2025 to provide more authentic and engaging content.

A key focus for 2025 will be expanding the brand to reach a wider audience across North and East Yorkshire.

Thank you to the York Against Cancer team and the Communications and Awareness Working Group Members.

www.yorkagainstcancerorg.uk 15

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

FUNDRAISING REPORT 2024

2024 saw another wonderful year of support from our volunteers, local businesses, organisations and groups alike. With fundraising growing, we have increased the team, to include an External Relations Manager and a Community Fundraiser.

We were lucky enough to have been supported by several businesses during 2024 with some fantastic fundraising results. Every penny raised help us to continue providing services, which we could not do without this level of support:


ut this level of support:
COMPANY RAISED
BarrattDevelopment £5,000.00
Arosa Caravan & Camping Park £4,155.00
HugsLtd £3,267.85
Hilton York Hotel £3,098.00
William Birch & Sons Ltd £2,995.70
Portakabin Limited £2,500.00
Ged Bell Butchers £2,205.10
Benevity £2,102.20
Ardent Uk £1,700.00
Darley Funeral Directors £1,508.41

Local Organisations are also key to our fundraising results, with some incredible efforts and support from the local community:

----- Start of picture text -----
Organisation Name Raised
Dunnington Cancer Support Group £20,000.00
Stamford Bridge Community Choir £6,214.78
The Blue Light Theatre Company £1,500.00
Chamber of Commerce £1,232.15
Archbishop Holgate School £1,165.22
St Michaels Church £1,068.55
----- End of picture text -----

Here a few of our events and the fantastic amounts raised:

www.yorkagainstcancerorg.uk 16

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Without the support and passion from our volunteers, supporters and team, fundraising would not be possible, so a huge THANK YOU to each and everyone who has helped York Against Cancer during 2024. We look forward to working with you and making 2025 fundraising just as successful.

When we are talking to prospective fundraisers, we like to tell them how the money they raise will be spent. The following graphic is used for this purpose.

York Against Cancer is committed to maintaining high standards of fundraising and retail activity. The Charity is registered with the Fundraising Regulator. The Charity has recognised and begun to put in place a comprehensive policy for fundraising. The Charity does not use any third parties to act on its behalf in relation to fundraising. No complaints were received by the charity during 2024 in relation to its fundraising activities.

FUTURE PLANNING

The Board have continued their consistently adopted policy of only making commitments when the finance for these is already in place. The Board are mindful of the responsibility of ensuring that the generous donations received are used in the most effective manner possible to meet with the aims of the charity.

With a sudden increase in legacies over the last few years the board established a Finance Sub‐ group to consider the most effective way to manage the funds for the future of the charity.

The Board has agreed with the recommendations of the sub‐group that a significant proportion of funds should be invested to provide for both future security of the charity and to ensure that the capital is used most effectively and to be available when future projects are considered and to ensure that the long‐term plans and services the charity provides can be continued into the foreseeable future.

www.yorkagainstcancerorg.uk 17

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, Governance and Management

The charity was incorporated on 22 April 2009 and its governing document is the memorandum and articles of association. The charity is a company limited by guarantee.

The charity is governed by a Board of Directors, supported by working groups as required. The Board members are all Trustees and include Officers of the Charity.

The Board meets four times a year and the various working groups meet as required during the year.

The members of the Board are volunteers. New Board members are elected by the existing members up to a maximum of twelve in total.

Trustee Induction and Training

New Trustees are briefed on their legal obligations under charity law, the committee and decision-making processes, the business plan and recent financial performance of the Charity. During their induction they meet key employees and other trustees. Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role. At the end of each three year tenure the trustees are required to update their trustee training.

Organisational Structure

The Board delegates the day-to-day management of the affairs of the Charity to Chief Executive Officer with assistance from a Board member, Tarnia Hudson, who serves as the Honorary Administrator.

Board membership

In March 2013 the Board adopted, by unanimous agreement, a protocol to introduce a threeyear rule from that date. Board members continue to actively seek new trustees, taking into consideration a good mix of professional skills including business, education and medical. A term of office for a director is 3 years, after which time he/she may be re-elected for a further 3-year term (details of current terms of office available on request).

Remuneration of key personnel

All members of staff employed by the charity have an annual appraisal in January following which salaries are set for the following 12 months. The appraisals are carried out by the Chief Executive Officer.

No Board member received any income or expenses for their work for the charity.

Related parties

The Charity owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited, a company registered in England and Wales. The subsidiary is used for the raising of funds for the Charity through the sale of bought in goods through the Charity’s two shops.

www.yorkagainstcancerorg.uk 18

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Risk management

The Trustees have assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and continues to take measures to reduce those risks to an acceptable minimum. The policy of only making new commitments when the funds are in hand is a very practical way of eliminating unnecessary financial risks. By its very nature a charity relies on fundraising, donations and legacies which can vary a great deal. Ongoing commitments are to our staff and to a range of time limited research and care projects.

The Board is proactive in identifying projects on which to spend its reserves, ensuring to find effective ways in which to fulfil the aims of York Against Cancer, whilst at the same time investing some funds to provide for future security.

Financial review and policies

The Charity’s funds in 2024 increased by £405,607 (2023 - decreased by £336,178). Prior to any adjustment for investments, the Charity made a surplus of £323,567 (2023 – deficit of £329,816). The largest new commitment in the year was £120,000 for the renewal of the clinical trial nurse posts for another 2 years.

The detail of funding of services and care activities can be found in note 6.

The principal funding sources are fund-raising, the trading shops, donations, and legacies. Gross income in 2024 amounted to £1,460,424 (2023 £763,604). These funds support the key objectives of the Charity, namely, to fund clinical research, to support people with cancer and to fund education about the disease.

The charity has continued to benefit from legacies during the year, and we are immensely grateful to the generous donors. Legacy income is unpredictable and is another reason why the charity must husband its resources in the most effective way to enable the services we provide to both continue and develop.

Investment powers and policy

The Trustees have a general power of investment and so have the discretion to invest in such investment assets as they see fit. The Trustees have set a policy that sufficient of the ‘free reserves’ should be invested to retain a reasonable liquidity to meet grant commitments.

Our policy is a medium low risk approach for the growth of the portfolio of investments. The investment managers have discretion about how the investments are managed within the policy parameters set by the Trustees.

The Investment Group oversees the investment management of the Charity’s funds. The services of HSBC Private Bank and Ruffer were retained as investment managers during 2024. Funds not invested are held on deposit to earn interest.

www.yorkagainstcancerorg.uk 19

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The total return on the investment portfolio managed by HSBC for the year ended 31 December 2024, before fees, was 9.86% (2023 8.33%). The total return on investment portfolio managed - by Ruffer for the year ended 31 December 2024, before fees, was 1.9% (2023 -6.6%).

Reserves Policy

The reserves policy is to ensure the charity holds sufficient funds for the continuation of our support services, whilst maintaining the ability to commitment to future projects. When the Leveson Centre was being planned the trustees understood that this would change the funding model needed for the Charity. The Leveson Centre will increase the operating costs of the charity as we bare all the costs for running the centre.

Cash reserves are accumulated before making a binding commitment to fund set term projects. The total funds held as at 31 December 2024 are £4,466,498 (2023 £4,060,891).

The Board is very mindful that the charity is wholly reliant on donated income and therefore has designated funds for future projects which are under consideration. This ensures its undesignated funds reflect the true level of reserves we hold for future operating commitments.

Undesignated Fund

These are reserves retained to provide working capital and funds for future projects. At the end of the financial year, the unrestricted undesignated reserves were £1,521,157 (2023 £1,093,281). The level of free reserves is £1,113,248 (after excluding lease commitments which we expect to be covered from future annual income). This is the equivalent of 12 months of our budgeted undesignated operating costs. It is the charity’s policy to hold 12 months of our operating costs as the charity is largely reliant on donated and legacy income.

Excess reserves will be available for additional fixed term projects or grants not already under consideration.

Designated Funds

Designated funds are part of the unrestricted funds which trustees have earmarked for assets held for the use in the charity and specific projects. At the year end, The Charity had consolidated designated funds of £2,713,980 (2023 £2,852,276) details of which are given in Note 16 of the financial statements.

Restricted Funds

Restricted funds represent monies raised by the Charity from public appeals for specific projects. At the year end, the Charity had restricted funds of £231,361 (2023 £115,334) details of which are given in Note 17 to the financial statements.

www.yorkagainstcancerorg.uk 20

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference and administrative details

Registered Charity number 1130835 Company number 06884476 Limited by Guarantee

Principal Office and Trading Address East Stand York Community Stadium Kathryn Avenue Huntington York YO32 9AF

Company Julie Pamela Russell Secretary Directors and Trustees Andrew Proctor Sarah Wearing Angela Darby Michael Sweet Rachel Goddard Robert Onyett Ian Yeowart Tarnia Hudson Prof Stephen Leveson Michael John Stower (resigned 31 December 2024) Trustee’s protocol available on request Accountants HPH Auditors Henton & Co LLP Chartered Accountants Chartered Accountants 54 Bootham 124 Acomb Road York Holgate YO30 7XZ York YO24 4EY Bankers National Westminster Solicitors Harrowells Bank 1 Market Street Moorgate House York Clifton Moorgate YO1 8SR York YO30 4WY Investment Advisors HSBC Global Asset Ruffer LLP Management 80 Victoria Street 78 St James’s Street London London SW1E 5JL SW1A 1EJ

www.yorkagainstcancerorg.uk 21

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

DIRECTORS’ AND TRUSTEES’ REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Directors and Trustees Responsibilities

The purpose of this statement is to distinguish the Directors’ and Trustees’ responsibilities for the financial statements from those of the auditors as stated in their report.

Company and charity law require the Directors and Trustees to prepare financial statements which give a true and fair view of the Charitable Company’s state of affairs at the end of its financial activities for that year. In preparing those financial statements the Trustees are required to:

The Directors and Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Charitable Company and enables them to ensure that the financial statements comply with the Companies Act 2006 and applicable charity law. They are also responsible for safeguarding the assets of the Charitable Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Directors and Trustees are aware:

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

Approved by the Board on 3 June 2025 and signed on its behalf by:

Ian Yeowart Director and Trustee

www.yorkagainstcancerorg.uk 22

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2024

Opinion

We have audited the financial statements of York Against Cancer (the 'parent charitable company') and its subsidiary (the ‘group’) for the year ended 31 December 2024 which comprise the group statement of financial activities, the group balance sheet, the charitable company balance sheet, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

www.yorkagainstcancerorg.uk 23

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2024

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matter on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 required us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees' responsibilities statement, the trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

www.yorkagainstcancerorg.uk 24

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER

YEAR ENDED 31 DECEMBER 2024

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

www.yorkagainstcancerorg.uk 25

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

INDEPENDENT AUDITORS' REPORT TO THE BOARD OF TRUSTEES OF YORK AGAINST CANCER YEAR ENDED 31 DECEMBER 2024

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the Charity's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charity's members those matters we are required to state to them in an auditors report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

………………………………………………..

Brett Davis (Senior Statutory Auditor)

For and on behalf of Henton & Co LLP

Chartered Accountants Statutory Auditor 124 Acomb Road York YO24 4EY

Date: ...........................................

www.yorkagainstcancerorg.uk 26

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2024

Note
Income and endowments from:
Donations and legacies
2
Other trading activities
3
Investments
4
Total
Expenditure on:
Raising funds
5
Charitable activities
6
Total
Net income/(expenditure)
before gains on investments
Net (losses)/gains on investments
11
Net income/(expenditure)
Transfers between funds
16
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
916,327
-
372,040
-
36,987
-
1,325,354
-
343,685
-
555,955
218,174
899,640
218,174
425,714
(218,174)
82,040
-
507,754
(218,174)
(79,878)
79,878
427,876
(138,296)
1,093,281
2,852,276
1,521,157
£
2,713,980
£
Unrestricted		 Restricted
Funds
£
135,070
-
-
135,070
-
19,043
19,043
116,027
-
116,027
-
116,027
115,334
231,361
£		 Year ended
31 Dec
2024
£
1,051,397
372,040
36,987
1,460,424
343,685
793,172
1,136,857
323,567
82,040
405,607
-
405,607
4,060,891
4,466,498
£		 Year ended
31 Dec
2023
£
430,282
287,169
46,153
763,604
321,182
772,238
1,093,420
(329,816)
(6,362)
(336,178)
-
(336,178)
4,397,069
4,060,891
£

The notes on pages 30 to 40 form part of these financial statements.

27

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER (Registration number: 06884476)

BALANCE SHEET AS AT 31 DECEMBER 2024

FIXED ASSETS
Tangible Fixed Assets
12
Investments
11
CURRENT ASSETS
Stock
Debtors
13
Cash at Bank and in Hand
CREDITORS: amounts falling due
within one year
14
TOTAL ASSETS LESS CURRENT
LIABILITIES
CREDITORS: amounts falling due
after one year
15
NET ASSETS
THE FUNDS OF THE CHARITY
Unrestricted
Undesignated
18
Designated
16,18
Restricted
17,18
TOTAL CHARITY FUNDS
NET CURRENT ASSETS
Note		 Charity
2024
£
914,103
2,980,639
3,894,742
-
989,056
313,129
1,302,185
425,599
876,586
4,771,328
249,981
£ 4,521,347
1,605,633
2,684,353
231,361
£ 4,521,347		 Consolidated
2024
£
943,730
2,980,638
3,924,368
82,186
845,035
364,669
1,291,890
499,779
792,111
4,716,479
249,981
£ 4,466,498
1,521,157
2,713,980
231,361
4,466,498
£		 Charity
2023
£
998,691
2,987,058
3,985,749
-
726,455
487,179
1,213,634
1,014,539
199,095
4,184,844
80,000
£ 4,104,844
1,171,819
2,817,691
115,334
£ 4,104,844		 Consolidated
2023
£
1,033,276
2,987,057
4,020,333
65,919
583,982
548,880
1,198,781
1,078,223
120,558
4,140,891
80,000
£ 4,060,891
1,093,281
2,852,276
115,334
£ 4,060,891

Approved by the Trustees on 3 June 2025 and signed on its behalf by:

S B Wearing Director and Trustee

The notes on pages 30 to 40 form part of these financial statements.

28

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

Note
Cash flows from operating activities:
Net cash used in operating activities
21
Cash flows from investing activities:
Dividends, interest and rents from investments
Purchase of property, plant and equipment
Proceeds from sale of property
Proceeds from sales of investments
Purchase of investments
Net cash provided by investing activities
Change in cash and cash equivalents in the
reporting period
Cash and cash equivalents at the beginning of
the reporting period
Cash and cash equivalents at the end of
the reporting period		 2024
£
(302,978)
36,987
(6,679)
-
813,121
(724,662)
118,767
(184,211)
548,880
£ 364,669		 2023
£
(484,244)
46,153
(405,743)
5,987
1,383,378
(860,300)
169,475
(314,769)
863,649
£ 548,880

The notes on pages 30 to 40 form part of these financial statements.

29

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES

Legal entity

York Against Cancer is regulated by the Charities Commission (1130835), limited by guarantee and is registered in England and Wales. The address of the registered office and principal place of business is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The consolidated accounts include the results of the Charitable Company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

No separate SOFA has been presented for the Charitable Company alone as permitted by the SORP.

The Charitable Company constitutes a public benefit entity as defined by FRS 102.

The accounts are presented in UK Sterling pounds (£).

Going Concern

The Charitable Company has cash resources and has no requirement for external funding. The Directors and Trustees have a reasonable expectation that the Charitable Company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

Income

Donations and legacies

Credit is taken for donations and subscriptions when they are received. Credit is taken for legacies when received or if, before receipt, there is sufficient evidence to provide the necessary certainty that the legacy will be received and the value of the incoming resources can be measured with sufficient reliability.

Other trading activities

Fundraising income - represents gross income from events.

Subsidiary's non-charitable trading turnover - represents gross income from York Against Cancer Trading Company Limited, the Charitable Company's trading subsidiary.

Investments

Investment income has been accounted for on an accruals basis.

Expenditure

Raising funds

Fundraising costs - represents the total costs of fundraising events and activities held during the year.

Non charitable trading expenditure - comprises of the direct costs and administrative costs of the Charitable Company's trading subsidiary, York Against Cancer Trading Company Limited.

Charitable activities

Direct costs - comprises of expenditure on various projects the Charitable Company is supporting and is accounted for in full when the Charitable Company commits to provide the funding.

Support costs - comprises of the salaries and office expenses of the Charitable Company.

Governance costs - comprises the costs associated directly with the management by the Directors/Trustees of the Charitable Company's activities, including audit fees and costs of meetings.

All costs are apportioned on an actual cost basis.

30

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1. ACCOUNTING POLICIES (continued)

Pension costs

The Charitable Company operates a defined contribution money purchase pension scheme for specific employees. The assets of the scheme are invested and managed independently of the finances of the Charitable Company. The charge for pension costs represents the contributions payable in the year.

Fixed Assets

Individual fixed assets costing £200 or more are capitalised and included in the accounts at cost.

Tangible fixed assets are depreciated over their expected useful lives at the following annual rates:

Freehold/Leasehold property at straight line over 50 years or life of lease Equipment - Shop and office equipment at straight line over 10 years - Computer equipment at straight line over 3 years - Respite home equipment at straight line over 4 years - Motor vehicles at 25% reducing balance

Stock

Stock is valued at the lower of cost and net realisable value. Cost is computed on a first in first out basis. Net realisable value is based on estimated selling price less the estimated cost of disposal.

Funds Structure

Unrestricted Funds are funds which are available for use or retention at the discretion of the Directors/Trustees, in accordance with the Charity's objects. Designated Funds represent unrestricted funds earmarked by the Directors/Trustees for particular purposes. Restricted Funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal. Details of Designated and Restricted Funds are contained in Notes 16 and 17, respectively.

Investments

The investment portfolios have been valued at market value at 31 December 2024. The SOFA includes the net gains and losses on investments arising on revaluation at the year end and on disposals throughout the year. Realised gains and losses on sales of investments are calculated as the difference between the sale proceeds and opening market value. Unrealised gains and losses represent the movement between market values.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and any short term deposit accounts with a maturity of three months or less from the date of opening.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

Rentals paid under operating leases are charged in the SOFA on a straight line basis over the lease term.

31

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

2.

NATIONS AND LEGACIES
In Memoriam
Legacies
Intangible income
Donations and grants		 Unrestricted
Restricted
2024
£
£
£
147,636
10,070
157,706
26,193
-
26,193
737,498
125,000
862,498
5,000
-
5,000
£ 916,327
£ 135,070
£ 1,051,397		 2023
£
185,542
22,360
217,380
5,000
£ 430,282

DONATIONS AND LEGACIES

During the year the charity was notified of a potential further legacy income from various estates. The timing and amounts still remain uncertain and therefore have not been provided for.

Intangible income comprises accounting services, a proportion of which is provided free of charge for the preparation of the Charitable Company and Subsidiary statutory accounts. A corresponding amount is included within governance costs.

3. OTHER TRADING ACTIVITIES

HER TRADING ACTIVITIES
Fundraising income
Subsidiary's non-charitable trading turnover
ESTMENTS
Interest received
Dividends received		 2024
£
182,132
189,908
£ 372,040
2024
£
50
36,937
£ 36,987		 2023
£
129,554
157,615
£ 287,169
2023
£
5,571
40,582
£ 46,153

4. INVESTMENTS

5. ANALYSIS OF RAISING FUNDS

ALYSIS OF RAISING FUNDS
Advertising
Fundraising costs
Non charitable trading - other costs
Non charitable trading - staff costs
Non charitable trading - depreciation
Investment fees		 Unrestricted
Restricted
2024
£
£
£
8,918
-
8,918
122,344
-
122,344
151,083
-
151,083
44,266
-
44,266
5,455
-
5,455
11,619
-
11,619
£ 343,685
£ -
£ 343,685		 2023
£
7,097
109,013
140,780
43,677
5,404
15,211
£ 321,182

32

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

6. ANALYSIS OF CHARITABLE ACTIVITES

Direct project costs:
Research
Jack Birch Unit
Clinical Trial Nurses
Support and Care
Leveson Centre - direct
Leveson Centre - staff
Leveson Centre - depreciation
Psychology services
Complementary therapy
Respite property expenses
Minibus running costs - direct
Minibus running costs - staff costs
Mobile Chemotherapy Unit
Transport - Rapid diagnostics
Cancer benefit advice service
One off costs
Support costs:
Staff costs
Staff training and travel
Rent, service charge and rates
Heat and light
Repairs and maintenance
Insurances
Printing, stationery and postage
Computer expenses
Telephone
Sundry expenses
Gains and losses on fixed assets
Depreciation
Governance costs:
Audit fees
Accountancy fees
Legal and professional fees
Bank charges
Total charitable activities		 Unrestricted
Restricted
2024
£
£
£
18,240
2,070
20,310
120,000
-
120,000
118,611
8,000
126,611
68,399
-
68,399
67,866
-
67,866
30,697
-
30,697
30,502
-
30,502
33,582
-
33,582
11,752
11,752
23,841
-
23,841
400
8,973
9,373
3,945
-
3,945
-
-
-
5,045
-
5,045
532,880
19,043
551,923
130,721
-
130,721
3,940
-
3,940
23,726
-
23,726
3,887
-
3,887
-
-
-
4,427
-
4,427
5,797
-
5,797
16,722
-
16,722
1,519
-
1,519
10,664
-
10,664
-
-
-
22,904
-
22,904
224,307
-
224,307
7,440
-
7,440
7,743
-
7,743
-
-
-
1,759
-
1,759
16,942
-
16,942
£ 774,129
£ 19,043
£ 793,172		 2023
£
-
5,144
111,384
53,049
56,287
16,855
16,212
29,970
10,411
22,602
20,069
4,948
160,000
320
507,251
146,138
4,118
35,885
4,465
132
5,565
4,271
11,342
816
8,680
(3,332)
25,061
243,141
7,440
7,760
5,670
976
21,846
£ 772,238

33

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

7. NET INCOMING RESOURCES FOR THE YEAR
NET INCOMING RESOURCES FOR THE YEAR 2024 2023
£ £
This is stated after charging:
Depreciation 96,225 86,752
Auditor's remuneration for audit services - charity 7,440 7,440

8. REMUNERATION AND EXPENSES OF TRUSTEES

None of the Trustees received any remuneration or benefits by virtue of being a Trustee of the Charity and no Trustees were reimbursed any expenses incurred for services provided to the Charity.

9. STAFF COSTS
Wages and salaries
Social security costs
Pension costs
Recruitment costs
Medical Insurance
Sub-contractor costs		 2024
£
286,686
20,618
11,070
1,819
4,533
-
£ 324,726		 2023
£
237,607
15,396
8,550
930
2,517
6,424
£ 271,424

The average monthly head count was 10 staff (2023 10) and the average monthly number of full-time equivalent employees (including casual and part-time staff) during the year were as follows:

e average monthly head count was 10 staff (2023 10) and the average
ual and part-time staff) during the year were as follows:		 monthly number of full-time equivalent employees (including
Projects 3 2
Trading 2 2
Management and administration 5 6

No employee received emoluments in excess of £60,000.

The key management personnel of the Charitable Company, comprise the directors and trustees, the CEO and Deputy CEO following the restructure. The total employee benefits of the key management personnel of the Charitable Company were £97,772 (2023 - £93,271).

10. SUBSIDIARY COMPANY

The Charitable Company owns the whole of the issued ordinary share capital of York Against Cancer Trading Company Limited. This company is registered in England and Wales (reg. no. 3405708) and its registered office is York Community Stadium, Kathryn Avenue, Huntington, York, England, YO32 9AF. The subsidiary is used for the raising of funds for the Charitable Company through the sale of bought in goods through the Charitable Company's shop and stalls. All activities have been consolidated on a line by line basis in the There is a loan account between the Charitable Company and the subsidiary. The balance on the loan account outstanding at the year end was £144,631 (2023 £149,404). Interest of £nil (2023 £nil) was charged during the year in respect of this loan.

A summary of the results of the subsidiary is shown below:

ummary of the results of the subsidiary is shown below:
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Profit on ordinary activities before taxation
Taxation
Profit on ordinary activities after taxation
Amount gifted to York Against Cancer
Retained (withdrawn from)/within Subsidiary
Net Assets		 2024
£
189,908
(98,153)
91,755
(102,652)
(10,897)
(10,897)
-
(10,897)
-
£ (10,897)
£ (54,847)		 2023
£
160,310
(82,637)
77,673
(107,224)
(29,551)
(29,551)
-
(29,551)
-
£ (29,551)
£ (43,950)

34

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

11. INVESTMENTS

Consolidated
Market value at 1 January 2024
Additions at cost
Disposals
Revaluations
Market value at 31 December 2024
Analysis of investments by class:
Listed investments
The historical cost of the above investments amounts to:
The following material investments are over 5% by value of the investments held
Ruffer Charity Assets Trust Account		 2024
£
2,987,057
724,662
(813,121)
82,040
£ 2,980,638
£ 2,980,638
£ 2,744,421
2024
Market value
£
1,482,817
£ 1,482,817		 2023
£
3,516,497
860,300
(1,383,378)
(6,362)
£ 2,987,057
£ 2,987,057
£ 2,710,556
2023
Market value
£
1,611,882
£ 1,611,882

The Charitable Company holds all of the issued shares of its subsidiary undertaking York Against Cancer Trading Company Limited, at cost of £1, in addition to the above investments.

TANGIBLE FIXED ASSETS
Cost
Additions in year
At 31 December 2024
At 31 December 2024
Depreciation
At 31 December 2023
At 1 January 2024
Charge for year
At 31 December 2024
Net book value
At 1 January 2024		 Subsidiary -
Motor
Charity
Shop
Property
Vehicles
Equipment
Total
Equipment
£
£
£
£
£
1,046,364
61,936
53,862
1,162,162
54,048
-
-
6,182
6,182
497
1,046,364
61,936
60,044
1,168,344
54,545
107,766
29,880
25,825
163,471
19,463
75,220
8,014
7,536
90,770
5,455
182,986
37,894
33,361
254,241
24,918
£ 863,378
£ 24,042
£ 26,683
£ 914,103
£ 29,627
£ 938,598
£ 32,056
£ 28,037
£ 998,691
£ 34,585		 Consolidated
Total
£
1,216,210
6,679
1,222,889
182,934
96,225
279,159
£ 943,730
£ 1,033,276

12. TANGIBLE FIXED ASSETS

All fixed assets are held for direct charitable purposes in Designated Funds.

35

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

13.
Amounts owed by subsidiary
Trade debtors
Prepayments
Accrued income
14. CREDITORS: amounts falling due
within one year
Trade creditors
Project creditors
Taxation and social security
Accruals
Other creditors
15. CREDITORS: amounts falling due
after one year
Project creditors
DEBTORS		 Charity
Consolidated
Charity
Consolidated
2024
2024
2023
2023
£
£
£
£
144,631
-
149,404
-
-
480
-
-
38,850
38,980
34,138
41,069
805,575
805,575
542,913
542,913
£ 989,056
£ 845,035
£ 726,455
£ 583,982
69,469 71,803 14,785 24,562
278,613
278,613 891,796
891,796
7,532
18,087 6,484
16,656
67,946
129,237 98,459
142,194
2,039
2,039
3,015
3,015
£ 425,599
£ 499,779
£ 1,014,539
£ 1,078,223
£ 249,981
£ 249,981
£ 80,000
£ 80,000

16. DESIGNATED FUNDS (consolidated)

Designated Funds - 2024
Leveson Centre
On demand services
Education Project
Jack Birch Unit
Fixed Assets Fund
Total
Designated Funds - 2023
Leveson Centre
On demand services
Education Project
Health Welfare
Jack Birch Unit
Fixed Assets Fund
Total		 Balance
Income
Expenditure
Transfers
Balance
01/01/2024
31/12/2024
£
£
£
£
£
243,000
-
(60,750)
-
182,250
66,000
-
(61,199)
73,199
78,000
10,000
-
-
-
10,000
1,500,000
-
-
-
1,500,000
1,033,276
-
(96,225)
6,679
943,730
£ 2,852,276
£ -
£ (218,174)
£ 79,878
£ 2,713,980
Balance
Income
Expenditure
Transfers
Balance
01/01/2023
31/12/2023
£
£
£
£
£
553,750
-
(60,750)
(250,000)
243,000
66,000
-
(36,780)
36,780
66,000
10,000
-
-
-
10,000
114,000
-
(114,000)
-
-
1,500,000
-
-
-
1,500,000
866,230
-
(83,419)
250,465
1,033,276
£ 3,109,980
£ -
£ (294,949)
£ 37,245
£ 2,852,276

Leveson Centre

The charity has set aside 5 years of lease costs of which 3 are remaining.

36

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

16. DESIGNATED FUNDS (consolidated continued)

On demand services

The Trustees have set aside monies to fund the following on demand services each year - patient travel for rapid diaognositics, complementary therapy and teenage psychology services. These services levels are set budgets at the beginning of each year based on current demand.

Education Project

The Board agreed to fund the annual budgeted costs of the Education Project which is aimed at raising the awareness of cancer to the public.

Jack Birch Unit

The Jack Birch Unit grant is up for renewal in July 2025 and the Trustees wish to continue this support the on-going research. Investments of £1.5m has been designated to ensure the charity can fund the continued support in 2025.

Fixed Asset Fund

This fund represents funds invested in tangible fixed assets.

Health Welfare

The board funded an additional health welfare post for 3 years in 2023 for the York area and ring fenced £114,000.

17. RESTRICTED FUNDS (consolidated)

Restricted Funds - 2024
Mobile Chemotherapy Unit
Jack Birch Unit
Leveson Centre
Health Welfare
Mouth Cancer
Total 2024
Restricted Funds - 2023
Mobile Chemotherapy Unit
Minibus Appeal
Mouth Cancer
Total 2023		 Balance
Income
Expenditure
Transfers
Balance
01/01/2024
31/12/2024
£
£
£
£
£
113,657
-
(8,973)
-
104,684
-
8,000
(8,000)
-
-
-
2,070
(2,070)
-
-
-
125,000
-
-
125,000
1,677
-
-
-
1,677
£ 115,334
£ 135,070
£ (19,043)
£ -
£ 231,361
Balance
Income
Expenditure
Transfers
Balance
01/01/2023
31/12/2023
£
£
£
£
£
133,726
-
(20,069)
-
113,657
-
100
(100)
-
-
1,677
-
-
-
1,677
£ 135,403
£ 100
£ (20,169)
£ -
£ 115,334

Mobile Chemotherapy Unit

The Mobile Chemotherapy Unit Appeal relates to funds raised for the specific purpose of running the service.

Jack Birch Unit

Money from restricted donations for the Jack Birch Unit were used to fund the additional monies needed for a fellowship.

Leveson Centre

Restricted donations for the leveson centre were used to fund the running costs of the centre.

Health Welfare

A legacy for £125,000 was received in the year for our Health Welfare Service. Our next renewal for this service will be in 2025 and these funds will go to support the continuation of this service.

Mouth Cancer

Monies raised for the Head and Neck cancer department.

Minibus Appeal

Monies were received for the running costs of the minibus in 2023 and the purchase of the new minibus which was in 2022.

37

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

18. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS

Fund balances at 31 December 2024
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities
Fund balances at 31 December 2023
are represented by:
Tangible fixed assets
Investments
Current assets
Current liabilities
Long term liabilities		 General
Designated
Restricted
Total
Funds
Funds
Funds
2024
£
£
£
£
-
943,730
-
943,730
1,480,638
1,500,000
-
2,980,638
790,279
270,250
231,361
1,291,890
(499,779)
-
-
(499,779)
(249,981)
-
-
(249,981)
£ 1,521,157
£ 2,713,980
£ 231,361
£ 4,466,498
General
Designated
Restricted
Total
Funds
Funds
Funds
2023
£
£
£
£
-
1,033,276
-
1,033,276
1,487,057
1,500,000
-
2,987,057
764,447
319,000
115,334
1,198,781
(1,078,223)
-
-
(1,078,223)
(80,000)
-
-
(80,000)
£ 1,093,281
£ 2,852,276
£ 115,334
£ 4,060,891

19. OPERATING LEASE COMMITMENTS

As at 31 December 2024 the group had the total minimum lease payments under operating leases at the end of the reporting period, for each of the following period:

period, for each of the following period:
At 31 December 2024 At 31 December 2023
Land and Office Land and Office
buildings equipment buildings equipment
Total operating leases payable: £ £ £ £
Within one year 120,187 - 120,187 -
Between two and five years 309,269 - 336,887 -
After five years 160,312 - 227,812 -

20. RELATED PARTIES

During the year the Charitable Company paid £3,094 (2023 £3,182) to HPH Chartered Accountants for accountancy services and software costs, a firm in which the Charitable Company's Treasurer, Sarah Wearing, is a partner. At the year end there was £nil (2023 £nil) owing to HPH Chartered Accountants.

During 2024 Trustees and related parties donated £5,654 (2023 - £6,100) to the charity.

38

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

21. CASH FLOW NOTES

Net income/(expenditure) for the reporting period
Adjustments for:
Depreciation charges
Gains on sale of fixed assets
(Gains)/Losses on investments
Dividends, interest and rents from investments
(Increase)/Decrease in stocks
(Increase)/Decrease in debtors
Increase/(Decrease) in creditors
Net cash used in operating activities
ANALYSIS OF CASH AND CASH EQUIVALENTS
Cash at bank and in hand
Total cash and cash equivalents
ANALYSIS OF CHANGES IN NET DEBT
At
01/01/2024
£
Cash
548,880
RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING
ACTIVITIES		 2024
2023
£
£
405,607
(336,178)
96,225
86,752
-
(3,332)
(82,040)
6,362
(36,987)
(46,153)
(16,267)
(5,398)
(261,053)
328,695
(408,463)
(514,992)
£ (302,978)
£ (484,244)
364,669
548,880
£ 364,669
£ 548,880
At
Cash-flows
31/12/2024
£
£
(184,211)
364,669

22. VOLUNTEERS

The Charity is fortunate to be supported by over 100 volunteers. Their activities include working in our shops, attending events, supporting the office, collections and baking. Without them the Charity could not achieve what it does; their support is a massive asset in both workforce and financial terms. Whilst going about their work they are also ambassadors for the Charity which encourages more people to volunteer and support.

With varied knowledge, skills and experience the volunteers make an invaluable group. Our thanks goes to them all – together we really do make a difference to cancer patients and their families.

39

Docusign Envelope ID: 9A9178FD-7E8E-4546-B508-5482270CF19B

YORK AGAINST CANCER

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

23. COMPARATIVE INFORMATION

Income and endowments from:
Donations and legacies
Other trading activities
Investments
Total
Expenditure on:
Raising funds
Charitable activities
Total
Net expenditure
before losses on investments
Net gains on investments
Net income/(expenditure)
Transfers between funds
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Total funds carried forward		 General
Designated
Fund
Funds
£
£
430,182
-
287,169
-
46,153
-
763,504
-
321,182
-
457,120
294,949
778,302
294,949
(14,798)
(294,949)
(6,362)
-
(21,160)
(294,949)
(37,245)
37,245
(58,405)
(257,704)
1,151,686
3,109,980
£ 1,093,281
£ 2,852,276
Unrestricted		 Restricted
Funds
£
100
-
-
100
-
20,169
20,169
(20,069)
-
(20,069)
-
(20,069)
135,403
£ 115,334		 Year ended
31 Dec
2023
£
430,282
287,169
46,153
763,604
321,182
772,238
1,093,420
(329,816)
(6,362)
(336,178)
-
(336,178)
4,397,069
£ 4,060,891

40